Self-Administered Drug Exclusion List (A53033) - R43 - Effective July 1, 2025

Date Posted: June 26, 2025

This billing and coding article has been revised and published for notice under contract numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).

Effective Date: July 1, 2025

Summary of Changes:

Added: Q5098 Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg*; Q5099 Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg*; and Q5100 Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg*

Revised: Q9998 descriptor from "INJECTION, USTEKINUMAB-AEKN (SELARSDI), 1 MG" to "Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg"

Visit the Self-Administered Drugs (SADs) webpage to view the Self-Administered Drug Exclusion List.

To view the complete listing of billing and coding articles and/or access the Active, Future, or Retired articles available in the CMS MCD, visit the Billing and Coding Articles webpage.

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )